[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100539338":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":31,"responsibleParty":49,"collaborators":20,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":59,"eligibilityCriteria":60,"healthyVolunteers":61,"sex":62,"minAge":63,"maxAge":64,"enrollmentInfo":65,"targetDuration":20,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":74,"overallStatus":34,"whyStopped":20,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"Global Stem Cell Center, Baghdad","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"bone marrow","EXPERIMENTAL","autologous bone marrow derived mononuclear cells injected 1cc per ovary for 2 ovaries under general anesthesia under ultrasound guide",[13],"Procedure: autologous bone marrow cells injection",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"PROCEDURE","autologous bone marrow cells injection","under general anesthesia bone marrow aspiration done followed by cell concentration and transvaginal ovarian injection",[9],null,[22,27],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"abdulmajeed hammadi, MD","CONTACT","+9647902268105","majeed51578@yahoo.co.uk",{"name":28,"role":24,"phone":29,"phoneExt":20,"email":30},"bushra alazzawi, MD","+9647705851195","khaliljumakareem69@gmail.com",[32],{"facility":33,"status":34,"city":35,"state":20,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"Ministry of Health","RECRUITING","Baghdad","964","Iraq","IQ",{"type":40,"coordinates":41},"Point",[42,43],44.40088,33.34058,{"lat":43,"lon":42},[46],{"name":47,"role":24,"phone":25,"phoneExt":20,"email":48},"abdulmajeed Hammadi, MD","alzaitounhospital@gmail.com",{"type":50,"investigatorFullName":51,"investigatorTitle":52,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"SPONSOR_INVESTIGATOR","abdulmajeed hammadi","clinical professor","100539338","treatment-of-premature-ovarian-insufficiency-using-bone-marrow-cells-100539338",false,"NCT06302543","Treatment of Premature Ovarian Insufficiency Using Bone Marrow Cells","Treatment of Premature Ovarian Insufficiency Using Autologous Bone Marrow Concentrates Through Transvaginal Approach Under Ultrasound Guidance","alfarah","Inclusion Criteria:\n\n1. clinical diagnosis of premature Ovarian insufficiency.\n2. ineffective hormonal therapy.\n3. biochemical evidence of high gonadotropins.\n\nExclusion criteria:\n\n1. solid or hematological malignancies.\n2. bleeding disorders.\n3. rejection of the procedure.",true,"FEMALE","30 Years","60 Years",{"count":66,"type":67},10,"ESTIMATED","INTERVENTIONAL",[70],"NA","investigator is doing single armed clinical interventional study to treat premature ovarian insufficiency with autologous bone marrow derived mononuclear cells to be given systematically and locally to the ovaries under ultrasound guidance with experienced gynecologist and to look for the results including: laboratory evidence through hormonal study ultrasound proof of ovarian follicle development. premature ovarian insufficiency is characterized by early loss of ovarian function (less than 40 years of age) manifested by menstrual irregularity or amenorrhea with elevated levels of gonadotropin hormones and low estrogen and anti-Mullerian hormone.\n\nAutologous use of stem cells from bone marrow are alternative safe minimal manipulative products that can provide a solution to this clinical problem without the need for oocyte donation program.",[73],"Premature Ovarian Insufficiency",[75],"premature ovarian failure,bone marrow,treatment","2025-08-02",{"date":78,"type":79},"2025-08-05","ACTUAL",{"date":81,"type":79},"2024-03-01",{"date":83,"type":67},"2026-03-10",{"name":51,"class":6},1]